Oral β2 agonist burns fat, spares muscle, avoids shots
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Karolinska Institutet and collaborators announced a new oral β2 agonist that activates skeletal muscle metabolism, offering a non‑appetite‑suppressing approach to type 2 diabetes and obesity.
- Phase I trial enrolled 48 healthy volunteers and 25 patients with type 2 diabetes, reporting the drug was safe and well tolerated.
- Animal studies showed the compound improved blood‑sugar regulation and increased fat burning while preserving muscle mass, avoiding side effects typical of GLP‑1 drugs such as Ozempic.
- Atrogi AB will lead a Phase II trial to test the pill’s efficacy in larger diabetic and obese populations, and the drug can be used alone or combined with existing GLP‑1 therapies.
- Funding came from the Swedish Research Council, Swedish Society for Medical Research, and the Novo Nordisk Foundation, while several authors hold equity or patents linked to Atrogi AB.
Why it matters: People with type 2 diabetes and obesity stand to benefit from a muscle‑preserving, oral medication that lowers blood sugar without suppressing appetite, while the market for injectable GLP‑1 drugs may see a new competing option; the pill’s tablet form also eliminates injections, potentially improving adherence and reducing treatment burden.
